Evidence map›Paper›PMID 38236842›Full record

ArticlePLoS neglected tropical diseases2024

Mpox: The alarm went off. Have we gone back to sleep?

Piero Olliaro, Josephine Bourner, Yap Boum Ii, Emmanuel Nakouné, Elise Pesonel, Amanda Rojek, Yazdan Yazdanpanah, François-Xavier Lescure, Alexandra Calmy, Beatriz Grinsztejn and 3 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Treatment of mpox with tecovirimat under expanded access use in the Central African Republic.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Article
  2. Article
  3. Article
  4. Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Piero OlliaroInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Josephine BournerInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4687-8380
Yap Boum IiInstitut Pasteur de Bangui, Bangui, Central African Republic.
Emmanuel NakounéInstitut Pasteur de Bangui, Bangui, Central African Republic.
Elise PesonelInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Amanda RojekInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Yazdan YazdanpanahANRS: Maladies Infectieuses Emergentes, Paris, France.
François-Xavier LescureInfectious diseases department, Bichat hospital, APHP, Paris Cité University, IAME UMRS 1137 Inserm, Paris, France.
Alexandra CalmyHôpitaux Universitaires de Genève, Geneva, Switzerland.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, FIOCRUZ, Rio de Janeiro, Brazil.
Peter HorbyInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Laura MersonInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
Jake DunningInternational Severe Acute Respiratory and emerging Infection Consortium (ISARIC), Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
NIAID NIH HHS UM1 AI069476Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mpox, MonkeypoxHumans

Identifiers

PMID38236842
PMCPMC10796058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.